THE ROLE OF ALLO-HSCT IN PATIENTS WITH ACUTE MYELOID LEUKEMIA IN COMPLETE MRD-NEGATIVE REMISSION AFTER THE FIRST COURSE OF INDUCTION (RESULTS OF A RANDOMIZED STUDY)

EHA Library, Irina Lukianova, 4208175

PROGNOSTIC MODEL FOR NEWLY DIAGNOSED M4/M5 ACUTE MYELOID LEUKEMIA TREATED WITH VENETOCLAX AND AZACITIDINE IN THE REAL-WORLD

EHA Library, Dan Wang, 4208176

ACUTE MYELOID LEUKEMIA (AML) PATIENT, DISEASE, AND MOLECULAR CHARACTERISTICS ASSOCIATED WITH A LONG-TERM RESPONSE TO OLUTASIDENIB

EHA Library, Stéphane De Botton, 4208177

LARGE LANGUAGE MODEL-ENHANCED CLINICAL RECORD ANNOTATION SUPPORTS RISK STRATIFICATION AND OUTCOME ANALYSES FOR AML PATIENTS TREATED WITH VENETOCLAX/AZACITIDINE FRONTLINE THERAPY

EHA Library, Xin Wang, 4208178

LONG-TERM FOLLOW UP OF ORAL DECITABINE/CEDAZURIDINE (ASTX727) PLUS VENETOCLAX IN NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA: A PHASE 2 STUDY

EHA Library, THURA WIN HTUT, 4208179

FRONTLINE LOW-INTENSITY VAH ACHIEVES HIGH MRD-NEGATIVE REMISSION RATES IN YOUNGER PATIENTS WITH NEWLY DIAGNOSED AML

EHA Library, Yannan Jia, 4208180

REVUMENIB AS MAINTENANCE FOR AML FOLLOWING ALLOGENEIC STEM CELL TRANSPLANTATION

EHA Library, Hannah Goulart, 4208181

VENETOCLAX-BASED THERAPY OR INTENSIVE CHEMOTHERAPY FOR THE FRONTLINE TREATMENT OF FIT PATIENTS WITH IDH1/2 MUTATION ACUTE MYELOID LEUKEMIA? A MULTI-CENTER, REAL-WORLD, COHORT STUDY

EHA Library, Guopan Yu, 4208182

REVUMENIB THERAPY POST HEMATOPOIETIC STEM CELL TRANSPLANT FOR PATIENTS WITH RELAPSED/REFRACTORY KMT2AR, NPM1M, AND NUP98R ACUTE MYELOID LEUKEMIA: POST HOC ANALYSIS OF OUTCOMES FROM AUGMENT-101

EHA Library, Andrius Žučenka, 4208183

VENETOCLAX COMBINED WITH MODIFIED INTENSIVE CHEMOTHERAPY IN NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA: A PROPENSITY SCORE-MATCHED ANALYSIS

EHA Library, Qiaoyi Zhou, 4208185

VENETOCLAX-BASED REGIMENS IMPROVE OUTCOMES IN ACUTE MYELOID LEUKEMIA WITH U2AF1 MUTATION: A REAL-WORLD EFFICACY COMPARATIVE ANALYSIS

EHA Library, Xiangli Chen, 4208186

TREATING ACUTE LEUKEMIA DURING PREGNANCY: MATERNAL AND FETAL OUTCOMES FROM A 34-YEAR EXPERIENCE

EHA Library, Fatima Alali, 4208187

SWEET SYNDROME IN ACUTE MYELOID LEUKEMIA: THE THREE-SITE MAYO CLINIC EXPERIENCE

EHA Library, Noah Takacs, 4208188

A PROSPECTIVE CLINICAL STUDY OF VENETOCLAX PLUS AZACITIDINE AS MAINTENANCE TREATMENT FOR POST-REMISSION ACUTE MYELOID LEUKEMIA

EHA Library, Jinqiang Guo, 4208189

ODYSSEY: A FIRST-IN-HUMAN STUDY OF THE ALDEHYDE DEHYDROGENASE (ALDH) INHIBITOR ABD-3001 IN PATIENTS WITH REFRACTORY/RELAPSED ACUTE MYELOID LEUKEMIA (AML) OR HIGH-RISK MYELODYSPLASTIC SYNDROME (MDS)

EHA Library, Mael Heiblig, 4208190

EVOLVING TREATMENT PATTERNS AND SURVIVAL IN OLDER ADULTS WITH ACUTE MYELOID LEUKEMIA: A POPULATION-BASED STUDY

EHA Library, Brittany Salter, 4208191

CPX-351 CONFERS SURVIVAL ADVANTAGE AS BRIDGE TO TRANSPLANT IN PATIENTS WITH TP53 MUTATED ACUTE MYELOID LEUKEMIAS THERAPY RELATED AND WITH MYELODISPLASTIC RELATED CHANGES ACHIEVING COMPLETE REMISSION

EHA Library, Elisabetta Todisco, 4208192

THE CHARACTERISTICS AND PROGNOSIS OF THERAPY-RELATED NPM1-MUTATED AML: A COMPARATIVE STUDY WITH DE NOVO NPM1-MUTATED AND THERAPY-RELATED AML IN CHINA

EHA Library, Xinyi Qi, 4208193

MOLECULAR PATTERNS AND THERAPY-SPECIFIC SURVIVAL OF PATIENTS (PTS) WITH IDH1-MUTATED ACUTE MYELOID LEUKEMIA (AML) WITH RESPECT TO SELF-REPORTED RACE-ETHNICITY

EHA Library, Jennifer Marvin-Peek, 4208194

INTENSIFIED INDUCTION CHEMOTHERAPY DOES NOT APPEAR TO IMPROVE OUTCOMES FOR PATIENTS WITH UPSTREAM BINDING TRANSCRIPTION FACTOR TANDEM DUPLICATIONS (UBTF-TD) AML: RESULTS FROM THE UK NCRI AML19 TRIAL.

EHA Library, Katie Lewis, 4208195

GENETIC CHARACTERISTICS AND PROGNOSTIC IMPACT OF MYC AND/OR KMT2A AMPLIFICATION MANIFESTING AS DOUBLE MINUTES IN ACUTE MYELOID LEUKEMIA

EHA Library, Tong Wang, 4208196

FRONTLINE TREATMENT INTENSITY MAY NOT SIGNIFICANTLY INFLUENCE SURVIVAL IN IDH-MUTATED AML

EHA Library, Tariq Kewan, 4208197

CLINICAL CHARACTERISTICS AND OUTCOMES OF ACUTE MYELOID LEUKEMIA WITH MECOM REARRANGEMENT: THE THREE-SITE MAYO CLINIC EXPERIENCE

EHA Library, Antoine Saliba, 4208198

EPIDEMIOLOGY, CLINICAL AND BIOLOGICAL CHARACTERISTICS OF UNFIT PATIENTS WITH CBF-AML: RESULTS FROM THE MULTINATIONAL PETHEMA REGISTRY

EHA Library, Evelyn Acuña-Cruz, 4208199

PERIPHERAL BLOOD FLOW CYTOMETRIC  MRD MONITORING IS FEASIBLE FOR AML PATIENTS

EHA Library, Nicholas McCarthy, 4208200

INTERIM RESULTS OF THE PHASE I/II STUDY INVESTIGATING KARONUDIB IN PATIENTS WITH REFRACTORY HAEMATOLOGICAL MALIGNANCIES PAIRED WITH EX-VIVO PRECISION SCREEN DRUG SENSITIVITY SCREENING

EHA Library, Stefan Deneberg, 4208201

CPX-351-INDUCED DEEP MOLECULAR REMISSION (MRD-) PREDICTS EXCELLENT OUTCOMES FOLLOWING ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN AML

EHA Library, Jannik Lüthje, 4208202

PATIENT TAILORED AZACITIDINE, VENETOCLAX AND GILTERITINIB TRIPLET THERAPY ACHIEVES DURABLE DISEASE CONTROL AND IMPROVES TOLERABILITY IN FLT3-MUTATED AML

EHA Library, Matilda Arvidsson Kvissberg, 4208203

ACUTE MYELOID LEUKEMIA WITH KMT2A AMPLIFICATION: A TP53-ALTERNATION ENRICHED, CHROMOANAGENESIS-DRIVEN ENTITY WITH POOR PROGNOSIS

EHA Library, THURA WIN HTUT, 4208204

OLDER AGE AND STAG2 MUTATIONS PREDICT SUPERIOR POST-TRANSPLANT SURVIVAL IN NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA TREATED WITH HMA-VENETOCLAX

EHA Library, Momna Warraich, 4208205

EFFICACY AND SAFETY ANALYSIS OF CBA CONDITIONING REGIMEN IN ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR INTERMEDIATE/HIGH-RISK ACUTE MYELOID LEUKEMIA

EHA Library, Qiuyue Wu, 4208206

VENETOCLAX-BASED REGIMENS IN ELDERLY OR MEDICALLY UNFIT PATIENTS WITH NEWLY DIAGNOSED CORE BINDING FACTOR (CBF)-REARRANGED AML: UPDATED REAL-WORLD OUTCOMES BASED ON INTERNATIONAL REGISTRY DATA

EHA Library, Leo Ruhnke, 4208207

INTERIM BONE MARROW BIOPSY IN AML TREATED WITH VENETOCLAX PLUS “7+3” CHEMOTHERAPY IS POORLY PREDICTIVE OF END-OF-INDUCTION REMISSION

EHA Library, Anushri Soni, 4208208

REDUCED DOSE ALL-TRANS RETINOIC ACID AND ARSENIC TRIOXIDE TO DECREASE EARLY DEATHS IN OLDER ACUTE PROMYELOCYTIC LEUKEMIA (APL) PATIENTS. POST-HOC ANALYSIS OF PATIENTS >60 YEARS IN THE EA9131 TRIAL

EHA Library, Vamsi Kota, 4208209

A PHASE 1/2 STUDY OF THE MENIN INHIBITOR REVUMENIB WITH THE CELMOD MEZIGDOMIDE IN RELAPSED/REFRACTORY KMT2A-REARANGED, NPM1-MUTANT, AND NUP98-REARRANGED ACUTE LEUKEMIAS

EHA Library, Kuo-Kai Chin, 4208210

EFFECT OF NPM1 MUTATION SUBTYPES AND CO-MUTATION PATTERN IN ACUTE MYELOID LEUKEMIA: A REAL-WORLD ANALYSIS FROM INTERNATIONAL COLLABORATION

EHA Library, Christopher Tham, 4208211

THE GLASGOW PROGNOSTIC SCORE ADDS PROGNOSTIC INFORMATION IN ELDERLY AML PATIENTS INELIGIBLE FOR INTENSIVE TREATMENT BEYOND THE MOLECULAR RISK PROFILE – A RETROSPECTIVE MULTICENTER ANALYSIS

EHA Library, Stefan Fuchs, 4208212

DETERMINING PROGNOSTIC FACTORS IN PATIENTS WITH POSITIVE PRE-TRANSPLANT MRD BASED ON SPECIFIC ABNORMALITIES IN 2022 ELN

EHA Library, Ruixin Li, 4208213

REAL-WORLD COMPARISON OF INTENSIVE CHEMOTHERAPY COMPARED TO NON-INTENSIVE TREATMENT OF MYELODYSPLASIA-RELATED ACUTE MYELOID LEUKAEMIA (AML-MR)

EHA Library, Trung Ngo, 4208214

HIGH REMISSION RATES AND COMPARABLE POST-REMISSION OUTCOMES WITH SHORTENED VENETOCLAX SCHEDULES IN A REAL-WORLD COHORT OF AZA-VEN TREATED AML PATIENTS

EHA Library, Anamarija Vrkljan Vuk, 4208215

EARLY BONE MARROW BLAST REDUCTION-GUIDED SELINEXOR-BASED REGIMEN THERAPY IN RELAPSED/REFRACTORY AND NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA

EHA Library, Donghua Zhang, 4208216

RUXOLITINIB COMBINED WITH DECITABINE INTENSIFIED MODIFIED BUSULFAN/CYCLOPHOSPHAMIDE CONDITIONING REGIMEN REDUCES RELAPSE AFTER ALLO-HSCT IN AML

EHA Library, Liping Dou, 4208217

PATIENT-SPECIFIC DIGITAL PCR MEASURABLE RESIDUAL DISEASE PREDICTS POST-TRANSPLANT OUTCOMES IN MYELODYSPLASIA-RELATED ACUTE MYELOID LEUKEMIA

EHA Library, Caroline Arvé, 4208218

A RELAPSE RISK SCORING SYSTEM FOR ACUTE MYELOID LEUKEMIA PATIENTS RECEIVING VENETOCLAX-BASED THERAPY

EHA Library, Yuxin Li, 4208219

OUTCOMES OF ACUTE PROMYELOCYTIC LEUKEMIA IN PATIENTS AGED ≥70 YEARS: A MULTICENTER REAL-WORLD ANALYSIS OF FIRST-LINE ATO-BASED THERAPY

EHA Library, Joana Infante, 4208220

WHOLE-GENOME PROFILING OF EARLY CLL/MBL REVEALS GENOMIC COMPLEXITY FROM DISEASE ONSET AND REFINES RISK BEYOND IPS-E

EHA Library, Pauline Robbe, 4208221

CHRONIC LYMPHOCYTIC LEUKEMIA HIJACKS THE GERMINAL CENTER-SPECIFIC TRANSCRIPTION FACTOR GFI1 TO DRIVE PROLIFERATION

EHA Library, Alba Maiques-Diaz, 4208222

SPATIAL TRANSCRIPTOMIC PROFILING OF THE LYMPH NODE MICROENVIRONMENT IN CHRONIC LYMPHOCYTIC LEUKEMIA

EHA Library, Carla Minoia, 4208223

DEFECTS IN MITOCHONDRIAL STRUCTURE UNDERLIE METABOLIC DYSFUNCTION IN T CELLS FROM PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA

EHA Library, Helga Simon-Molas, 4208224

INTEGRATED TRANSCRIPTOMIC AND IMMUNE PROFILING IDENTIFIES DETERMINANTS OF DEEP REMISSION WITH IBRUTINIB–VENETOCLAX COMBINATION THERAPY IN CHRONIC LYMPHOCYTIC LEUKEMIA

EHA Library, Varsha Gandhi, 4208225

TRANSCRIPTIONAL AND IMMUNOGENETIC DIVERSITY IN STEREOTYPED CHRONIC LYMPHOCYTIC LEUKEMIA: INSIGHTS FROM SINGLE-CELL SEQUENCING

EHA Library, Blaž Oder, 4208226

IL21-ARMORED CD72-TARGETING NANOBODY-BASED CAR-NK AS AN OFF-THE-SHELF, SAFE AND EFFECTIVE APPROACH TO ELIMINATE CHRONIC LYMPHOCYTIC LEUKEMIA AND RICHTER TRANSFORMATION CELLS

EHA Library, Daniel Gil-Alós, 4208227

MECHANISMS OF RESISTANCE TO BTK INHIBITORS INDEPENDENT OF BTK AND PLCG2 MUTATIONS

EHA Library, Wen Li, 4208228

MALT1 IS REQUIRED FOR IN VIVO CHRONIC LYMPHOCYTIC LEUKEMIA DEVELOPMENT

EHA Library, Nakhle Saba, 4208229

MATURE B-CELL NEOPLASMS ARE ASSOCIATED WITH A PROLONGED PRECURSOR PHASE CHARACTERIZED BY IGH GENE REPERTOIRE CLONALITY

EHA Library, Pieter Martijn Kolijn, 4208230

FIRST-IN-HUMAN IN VIVO CAR T CELL GENERATION USING A CD8-TARGETED LIPID NANOPARTICLE PLATFORM IN RELAPSED/REFRACTORY B-CELL LYMPHOMA

EHA Library, Xiangrong Song, 4208231

CD20×CD3 BISPECIFIC ANTIBODY ENHANCES AND EXTENDS IBRUTINIB-MEDIATED DISEASE CONTROL IN CLL IN 3D CULTURE MODELS AND IN MICE

EHA Library, Cèlia Dobaño-López, 4208232

SPATIAL TRANSCRIPTOMICS UNCOVERS A BONE MARROW NICHE SUPPORTING BI-DIRECTIONAL CROSSTALK BETWEEN MONOCYTES/MACROPHAGES AND T-CELL LARGE GRANULAR LYMPHOCYTIC LEUKEMIA CELLS

EHA Library, Mischa Vervoordeldonk, 4208233

ZNF292 MUTATIONS IMPACT CELL CYCLE DYNAMICS AND COMPROMISE REPLICATION STRESS RESPONSE, DEFINING A POOR PROGNOSTIC SUBGROUP IN CHRONIC LYMPHOCYTIC LEUKEMIA

EHA Library, Alberto Rodríguez-Sánchez, 4208234

TARGETING THE FATTY ACID TRANSPORTER SLC27A1 IMPAIRS METABOLIC FITNESS AND ENHANCES DRUG SENSITIVITY IN CHRONIC LYMPHOCYTIC LEUKEMIA

EHA Library, Patrycja Tarkowska, 4208235

RESTORATION OF MIR-146B IN T-CELL LARGE GRANULAR LYMPHOCYTE LEUKEMIA (T-LGLL): SELECTIVE MOLECULAR REPROGRAMMING TOWARD AN RNA-BASED TARGETED THERAPEUTIC STRATEGY

EHA Library, Elisa Rampazzo, 4208236

CLINICAL AND TRANSCRIPTOMIC INSIGHTS INTO THE NPM1-XPO1 AXIS IN CHRONIC LYMPHOCYTIC LEUKEMIA AND ITS IMPLICATIONS FOR TARGETED THERAPY

EHA Library, Monika Szelest, 4208237

DISTINCTIVE IN VIVO CLASS-SWITCH RECOMBINATION PATTERNS IN CHRONIC LYMPHOCYTIC LEUKEMIA STEREOTYPED SUBSET #1: MOLECULAR EVIDENCE FOR TUMOR MICROENVIRONMENT-DRIVEN ACTIVATION

EHA Library, Aikaterini Mallou, 4208238

INCREASED SMU-3′RR RECOMBINATION RESULTING FROM MYC OVEREXPRESSION AFTER HEIGHTENED ACTIVATION IN CLL FURTHER SUPPORTS A ROLE FOR C-MYC AS A DRIVER OF GENOMIC INSTABILITY

EHA Library, Sophie Peron, 4208239

ANALYSIS OF CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) PATIENTS WITH 11Q DELETION: CLINICOBIOLOGICAL PROFILE AND GENOMIC CHARACTERIZATION BY OGM

EHA Library, Joanna Kamaso, 4208240

INITIAL RESULTS OF MULTICENTER PHASE 2 BOVEN-ΔMRD400 TRIAL OF ZANUBRUTINIB, OBINUTUZUMAB, AND VENETOCLAX (BOVEN) WITH TREATMENT DURATION GUIDED BY MRD KINETICS (ΔMRD400) IN TREATMENT-NAÏVE (TN) CLL

EHA Library, Jacob Soumerai, 4208241

UPDATED RESULTS FROM A PHASE 1B STUDY OF NON-COVALENT PAN-MUTANT BTK INHIBITOR DOCIRBRUTINIB (AS-1763) IN PATIENTS WITH PREVIOUSLY TREATED B-CELL MALIGNANCIES

EHA Library, Nitin Jain, 4208242

ERIC REAL-WORLD RETROSPECTIVE ANALYSIS OF OUTCOMES IN CLL PATIENTS TREATED WITH CHEMOTHERAPY-FREE FRONTLINE TARGETED THERAPIES DEMONSTRATES THE IMPACT OF TP53 DISRUPTION IN THE ERA OF NOVEL THERAPY.

EHA Library, Sunil Iyengar, 4208243

UPDATED CLINICAL DATA FROM THE PHASE 1 STUDY OF DIBOTATUG (DR-01), A NON-FUCOSYLATED ANTI-CD94 ANTIBODY, IN PATIENTS WITH LARGE GRANULAR LYMPHOCYTIC LEUKEMIA

EHA Library, Tapan Kadia, 4208244

BRUTON TYROSINE KINASE (BTK) DEGRADER BGB-16673 IN BTK INHIBITOR–NAIVE PATIENTS WITH CLL/SLL AND OTHER B-CELL MALIGNANCIES: RESULTS FROM THE PHASE 1 CADANCE-101 STUDY

EHA Library, Irina Mocanu, 4208245

CLINICAL, CELLULAR AND MOLECULAR EFFECTS OF SUSPENDED AND REPEATED (ON-OFF) IBRUTINIB TREATMENT IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA IN SUSTAINED PARTIAL REMISSION.

EHA Library, Marzia Palma, 4208246

ACALABRUTINIB TREATMENT ACHIEVES DURABLE RESPONSES AND QUALITY OF LIFE IMPROVEMENTS IN OLDER (≥80Y) AND/OR FRAIL PATIENTS WITH CLL – FINAL ANALYSIS OF THE CLL-FRAIL TRIAL

EHA Library, Florian Simon, 4208247

INCIDENCE OF REAL-WORLD CARDIOVASCULAR (CV) EVENTS IN PATIENTS INITIATING COVALENT BTK INHIBITORS (CBTKI) IN 1L CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) IN THE UNITED STATES

EHA Library, David Dingli, 4208248

UPDATED SAFETY AND EFFICACY OF ALL‑ORAL SONROTOCLAX + ZANUBRUTINIB IN RELAPSED/REFRACTORY (R/R) CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA (CLL/SLL), INCLUDING PATIENTS WITH DEL(17P)/TP53

EHA Library, Stephen Opat, 4208249

REAL-WORLD CARDIOVASCULAR BURDEN, TREATMENT (TX) SEQUENCES, AND CLINICAL OUTCOMES IN PATIENTS INITIATING 1L COVALENT BRUTON’S TYROSINE KINASE INHIBITORS (CBTKIS) IN CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)

EHA Library, David Dingli, 4208250

SECONDARY CANCERS IN CLL PATIENTS TREATED WITH TARGETED THERAPIES AT FIRST LINE: A REAL-WORLD COMPARATIVE STUDY

EHA Library, Liron Hofstetter, 4208251

TREATMENT AND OUTCOMES OF ACCELERATED CHRONIC LYMPHOCYTIC LEUKEMIA/ SMALL LYMPHOCYTIC LYMPHOMA IN THE TARGETED THERAPY ERA

EHA Library, Robert Puckrin, 4208252

PIRTOBRUTINIB IN TREATMENT-NAÏVE PATIENTS WITH CLL/SLL: POOLED RESULTS FROM BRUIN CLL-313 AND BRUIN CLL-314

EHA Library, Jennifer Woyach, 4208253

UNDETECTABLE MINIMAL RESIDUAL DISEASE AND SURVIVAL ASSOCIATION IN OVER 4000 FIRST-LINE CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS: ARTIFICIAL INTELLIGENCE–ASSISTED PATIENT-LEVEL PATIENT ANALYSES

EHA Library, Anthony Mato, 4208254

LONG-TERM FOLLOW-UP FOR SAFETY AND EFFICACY OF ZANUBRUTINIB IN ELDERLY (≥80 YEARS) TREATMENT‑NAÏVE CLL/SLL PATIENTS, INCLUDING THOSE WITH DEL(17P): SUBGROUP ANALYSIS FROM THE SEQUOIA TRIAL

EHA Library, Alessandra Tedeschi, 4208255

STAT3-MUTATED LARGE GRANULAR LYMPHOCYTIC LEUKEMIA: A RETROSPECTIVE ANALYSIS OF AN ITALIAN REFERRAL CENTRE

EHA Library, Luca Massarotti, 4208256

CARDIOVASCULAR TOXICITY OF CONTEMPORARY FIRST-LINE CLL TREATMENT REGIMENS: A POOLED ANALYSIS OF THE GERMAN CLL STUDY GROUP

EHA Library, Florian Simon, 4208257

QUALITY OF LIFE AND SYMPTOMS WITH FIXED-DURATION ACALABRUTINIB + VENETOCLAX ± OBINUTUZUMAB VS CHEMOIMMUNOTHERAPY IN TREATMENT-NAIVE CHRONIC LYMPHOCYTIC LEUKEMIA: PATIENT-REPORTED OUTCOMES FROM AMPLIFY

EHA Library, Arnon Philip Kater, 4208258

NEMTABRUTINIB PLUS VENETOCLAX IN PARTICIPANTS WITH RELAPSED OR REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA: PART 1 OF THE PHASE 3 BELLWAVE-010 STUDY

EHA Library, Paolo Ghia, 4208259

BRUTON TYROSINE KINASE INHIBITORS NEUTRALIZE THE ADVERSE PROGNOSIS IMPACT OF THE IGLV3-21R110 MUTATION IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA

EHA Library, Juan A. Piñeyroa, 4208260

MATURE LYMPHOID NEOPLASMS IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA: RESULTS FROM THE SPANISH MULTICENTER GELLC STUDY

EHA Library, Miguel Argüello de Tomás, 4208261

REAL-WORLD COMPARATIVE ANALYSIS OF TREATMENT DISCONTINUATION WITH COVALENT BRUTON TYROSINE KINASE INHIBITORS IN FIRST-LINE CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)

EHA Library, Nakhle S. Saba, 4208262

BGB-16673, A BRUTON TYROSINE KINASE (BTK) DEGRADER, HAS LOW RISK OF CYP3A-MEDIATED DRUG-DRUG INTERACTION (DDI): PHASE 1 ABSORPTION, DISTRIBUTION, METABOLISM, AND EXCRETION AND DDI STUDY RESULTS

EHA Library, Bilal Tariq, 4208263

REAL WORLD OUTCOMES IN OF 50 PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) TREATED WITH PIRTOBRUTINIB AFTER A COVALENT BRUTON TYROSINE KINASE INHIBITOR AND A BCL2 INHIBITOR: A GIMEMA STUDY

EHA Library, Antonio Cuneo, 4208264

CORRELATION OF BASELINE CHARACTERISTICS WITH PROGNOSIS IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA (CLL/SLL) TREATED WITH LISAFTOCLAX (APG-2575) IN A PIVOTAL PHASE 2 STUDY

EHA Library, Keshu Zhou, 4208265

BTKI-FIRST VERSUS VENETOCLAX-OBINUTUZUMAB-FIRST SEQUENCING IN CLL: A PROPENSITY SCORE-MATCHED TOTAL DISEASE MANAGEMENT ANALYSIS

EHA Library, Shankar Biswas, 4208266

REAL-WORLD DATA OF FIRST-LINE FIXED-DURATION WITH IBRUTINIB-VENETOCLAX (IV) OR VENETOCLAX-OBINUTUZUMAB (VO) IN CHRONIC LYMPHOCYTIC LEUKEMIA: A MULTICENTER STUDY FROM THE GELLC REGISTRY

EHA Library, Lucrecia Yáñez, 4208267

YIELD AND APPROPRIATENESS OF IMMUNOPHENOTYPING IN MILD LYMPHOCYTOSIS: A 6-YEAR SINGLE-CENTRE ANALYSIS OF OVER 1000 TESTS

EHA Library, Firinna McKenna Beattie, 4208268

TREATMENT OUTCOMES WITH FIRST-LINE VENETOCLAX+OBINUTUZUMAB THERAPY IN YOUNGER ADULTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA: A REAL-WORLD, INTERNATIONAL STUDY

EHA Library, Andres Chang, 4208269

ZANUBRUTINIB VS IBRUTINIB IN TREATMENT-NAIVE CHRONIC LYMPHOCYTIC LEUKEMIA (CLL): IMPLICATIONS FOR INTERPRETING FIXED-DURATION TREATMENT OUTCOMES FROM CLL17

EHA Library, Talha Munir, 4208270

MORPHOLOGY-BASED CELL SORTING USING AI-DRIVEN GHOST CYTOMETRY COMBINED WITH SINGLE-CELL RNA SEQUENCING REVEALS POTENTIAL THERAPEUTIC TARGETS IN CML LEUKEMIC STEM CELLS

EHA Library, Tomoiku Takaku, 4208271

CITE-SEQ RESOLVES THE LEUKEMIC STEM CELL HIERARCHY AND IMMUNE MICROENVIRONMENT IN CML DISEASE PROGRESSION VIA MACHINE LEARNING MODELS

EHA Library, Kristina Kirschner, 4208272

DUAL TARGETING WITH PONATINIB AND CRIZOTINIB TO OVERCOME ASCIMINIB RESISTANCE IN CHRONIC MYELOID LEUKEMIA

EHA Library, Seiichi Okabe, 4208273

METABOLOMIC PROFILING REVEALS SUBTYPES WITH DISTINCT METABOLIC FEATURES AND PROGNOSIS IN CLL PATIENTS

EHA Library, Huayuan Zhu, 4208274

NEW 2-AMINOPYRIMIDINE PONATINIB DERIVATIVES AS POTENTIAL BCR-ABL1 TYROSINE KINASE INHIBITORS IN CHRONIC MYELOID LEUKEMIA

EHA Library, Ana Ribeiro, 4208275